Helixon

Helixon (华深智药) is a global AI-powered biotech company specializing in drug discovery, with headquarters in Beijing and operations in Shanghai and Suzhou, China. Founded in 2023, Helixon has assembled an interdisciplinary team with expertise in machine learning, structural biology, and medicinal chemistry to build a next-generation AI scientific computing platform combined with proprietary high-throughput biological experimentation technology. The company operates through a US-affiliated entity called Earendil Labs, which entered a landmark partnership with Sanofi valued at over $1.8 billion for immune disease drugs HXN-1002 and related compounds. Helixon's model leverages AI to design large molecules, rapidly test them in China, and license out validated drug candidates to global pharmaceutical partners. The company is backed by multiple Chinese venture capital firms and is recognized as a leading player in China's AI drug discovery ecosystem, alongside Insilico Medicine and XtalPi.